Kylie Renee James

University of New South Wales
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

IBD pathogenesis is underpinned by an imbalance between excess inflammation caused by effector T-cells and inadequate suppression by regulatory T-cells (Tregs). Interleukin-37 (IL-37) is a potent, anti-inflammatory cytokine that signals via its receptors IL-1R5 and IL-1R8. Hence, augmenting anti-inflammatory mechanisms that drive IL-37 expression is a strategy to control IBD-associated inflammation. However, the role of IL-37 and its receptors in T-cells remains incompletely understood. Here, we investigated T-cell expression profiles of IL-37 and its receptors to understand the drivers of dysregulated T-cell responses in IBD and develop novel, more effective therapies. T-cell subsets from healthy control (HC), Crohn’s disease (CD) and ulcerative colitis (UC) peripheral blood mononuclear cells (PBMC) and lamina propria mononuclear cells (LPMC) were assessed for expression of IL-37 and its receptors by flow cytometry. CD3+IL-1R8+ T-cell transcriptomes underwent RNA sequencing. The phenotype and suppressive capacity of Tregs supplemented with IL-37 was assessed in vitro. Our results indicate that IL-37 and its receptors were differentially expressed among PBMC and LPMC T-cell subsets in IBD patients compared to HC. Transcription signatures unique to IBD were revealed, particularly histone and mitochondrial pathways. Remarkably, culturing Tregs with IL-37 preserved FOXP3 expression and suppressiveness at a level comparable to treatment with the well-established Treg stabilizing agent rapamycin. Altogether, our study identified differences in T-cells expressing IL-37 and its receptors that are indicative of T-cell dysfunction in IBD. These findings highlight a novel and promising avenue for restoring immune homeostasis in IBD by targeting and boosting the IL-37 signalling pathway.

Year:

2026

Year:

2026

Year:

2026

Year:

2024

Identifying cell intrinsic regulators of immune sexual dimorphism is critical for treatment of several immunopathologies. We show that Malat1 is required for appropriate cytokine expression in female but not male Th2 cells. Malat1 deficiency impairs in vitro Th2 differentiation of naïve CD4 + T cells from female mice, characterised by transcriptome-wide effects and suppression of cytokine expression, particularly IL10. Upon IL10R blockade a pronounced effect is also seen on IL4 and IL13. Mechanistically, naïve CD4 + T cells from Malat1 -/- female mice demonstrate altered early activation kinetics and impaired early differentiation gene expression, including up-regulation of an interferon stimulated gene (ISG) module. This is followed by suppression of IL2Rα and IL2Rγ expression and IL2-mediated differentiation. Mimicking the effect of Malat1 loss by maintaining early ISG expression in WT cells with IFNβ treatment partially phenocopies the effects of Malat1 deficiency. A subset of the effects of Malat1 loss in female cells is also observed in male cells. However, this does not affect endpoint Th2 differentiation. Male CD4 + T cells demonstrate stronger early activation, higher ISG expression during early differentiation, maintenance of IL2Rα expression independently of Malat1 , and lower sensitivity to exogenous IL2 during late differentiation compared to female cells. In vivo , female, but not male, Malat1 -/- mice demonstrate altered Th2 cytokine expression characterised by a reduction in IL10 + Th2 cells in both lung and spleen following priming and challenge with Schistosoma mansoni eggs, a model of lung type 2 inflammation. Overall, these findings reveal Malat1 as a novel determinant of immune sexual dimorphism.

Year:

2024

The gastrointestinal (GI) tract consists of connected organs, from the oral cavity to rectum, which function to ensure efficient nutrient uptake and barrier immunity. Diseases of the GI tract affect millions worldwide and as such there are now over 25 published single cell RNA-sequencing (scRNAseq) datasets surveying the GI tract, profiling specific anatomical regions, cell lineages, ages and diseases. To consolidate these efforts, we harmonised and integrated scRNAseq datasets across the whole GI tract from developing and adult human tissues, as well as newly generated data from preterm gut. We uniformly processed 385 samples from 189 healthy controls using a newly developed automated QC approach (scAutoQC). In total, our healthy reference contains ~1.1 million cells which we annotated to a total of 137 fine-grained cell states. We anchor 13 published and 1 unpublished GI disease datasets covering gastric and colorectal (CRC) cancers, celiac disease, ulcerative colitis (UC) and Crohn's disease (CD) to this reference, taking our atlas to a total of 1.6 million cells. We provide our atlas as a valuable resource to the community (available at gutcellatlas.org). Using this resource, we discover epithelial cell metaplasia arising from stem cells across intestinal inflammatory diseases (celiac, UC and CD) and CRC with transcriptional similarity to cells of the gastric and Brunner's glands. Whilst previously linked to mucosal healing, we now implicate these cells in inflammation through recruitment of immune cells including T cells and neutrophils, and through direct interactions with T cells. Overall, we discover a shift in paradigm whereby changes in stem cells during inflammation lead to altered mucosal tissue architecture, which in turn contributes to ongoing inflammation. These findings highlight that in addition to barrier function, epithelial cells actively contribute to progression of inflammation which may be a function applicable to other tissues and diseases.

Year:

2024

Primary sclerosing cholangitis (PSC) is a chronic progressing cholestatic disease that often co-occurs with inflammatory bowel disease (PSC-IBD). PSC-IBD affecting the colon (PSC-UC) is likened clinically to ulcerative colitis (UC), however differences include a right colon dominance, less severe inflammatory presentation and a greater lifetime risk of colorectal cancer. To understand the basis of clinical differences, we combine single-cell mRNA and antigen receptor sequencing, 16S ribosomal DNA analysis and spatial transcriptomics on biopsies from multiple colon regions of both PSC-UC and UC patients in remission or at the time of relapse. We discover disease-specific cell and microbial profiles between these cohorts, highlighting a distinct landscape in the right colon of PSC-UC patients and an epithelial-endothelial cell state that may contribute to intestinal permeability in UC. We show the expansion of an activated mast cell state in both diseases during flare, and demonstrate the requirement of TMEM176B in sustaining this activated state. Together this work demonstrates that PSC-UC and UC are distinct diseases with common cell mechanisms during inflammation, providing cellular and microbial insights to improve treatment of both patient cohorts.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (26)

Kourosh Saeb-Parsy

Reader

University of Cambridge

UNITED KINGDOM
View details

Ruoyan Li

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Chris Bacon

Clinical Senior Lecturer/Consultant

Newcastle University

UNITED KINGDOM
View details

Semir Beyaz

Principal Investigator

Cold Spring Harbor Laboratory

UNITED STATES
View details

Jellert Gaublomme

Assistant Professor

Columbia University

UNITED STATES
View details

Lori Coburn

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Christopher J Stewart

Professor of Human Microbiome Research

Newcastle University

UNITED KINGDOM
View details

Julio Saez-Rodriguez

Head of Research

European Bioinformatics Institute

UNITED KINGDOM
View details

Sarah Teichmann

University of Cambridge

UNITED KINGDOM
View details

John McNeil

MONASH UNIVERSITY

AUSTRALIA
View details

Joshua Ooi

Head, Regulatory T cell Therapies

Monash University Malaysia.

AUSTRALIA
View details

Alison Simmons

Director

University of Oxford

UNITED KINGDOM
View details

Frode Jahnsen

Professor at University of Oslo

University of Oslo

NORWAY
View details

Jose Ordovas-Montanes

Research Faculty

Boston Children's Hospital

UNITED STATES
View details

Sebastian Lobentanzer

Principal Investigator

Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit

GERMANY
View details

James Whisstock

Professor

MONASH UNIVERSITY

AUSTRALIA
View details

Claudia Nold

Professor

Monash University Malaysia.

AUSTRALIA
View details

Marcel F. Nold

MONASH UNIVERSITY

AUSTRALIA
View details

Jacqueline Tearle

Garvan Institute of Medical Research

AUSTRALIA
View details

paul klenerman

University of Oxford

UNITED KINGDOM
View details

James Hewitson

Senior Lecturer in Biomedical Sciences

University of York

UNITED KINGDOM
View details

Matthias Zilbauer

University of Cambridge

UNITED KINGDOM
View details

Alexander Predeus

Principal bioinformatician

Wellcome Sanger Institute

UNITED KINGDOM
View details

Benjamin J Stewart

Clinical Lecturer

University of Cambridge

UNITED KINGDOM
View details

Simon Koplev

Assistant Professor at KTH Royal Institute of Technology

KTH Royal Institute of Technology

SWEDEN
View details

Ioannis Kourtzelis

Senior Lecturer in Immunology

University of York

UNITED KINGDOM
View details